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Abstract
Ibuprofen and its major metabolites were incubated with catalase and fumarase, in the presence of protein-modifying biomolecules, to
explore the mode of action of ibuprofen in protection against cataract. Both 2 and 10 mM ibuprofen/metabolites protected catalase against
fructose-, cyanate- and prednisolone-induced inactivation; the carboxy-metabolite gave the highest protection (31%). The 2 mM ibuprofen/
metabolites protected fumarase against fructose- and cyanate-induced inactivation by up to 26%, but had no effect on prednisolone-induced
inactivation. Ibuprofen/metabolites did not bind to catalase or fumarase. They penetrated into the lens in vitro. When in the lens, the
metabolites may reduce the risk of cataract by protecting lenticular enzymes. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Nonenzymatic posttranslational modification of proteins
by biomolecules, such as sugars, has been implicated in
aging and in age-related diseases, including cataract [1,2]
and Alzheimer’s disease [3], and in complications of dia-
betes [4,5] and renal failure [6]. In tissues with low or no
protein turnover, such as the lens nucleus, and when the
protein turnover mechanism is overwhelmed by high levels
of deleterious compounds, as in diabetes and renal failure,
the chemically modified proteins will accumulate with
detrimental effect on their functions. The lower activity of
enzymes in cataract is believed to be due to their structural
modifications by the damaging agents [1,7,8].
There is growing evidence for a protective role of
ibuprofen and other nonsteroidal anti-inflammatories in
age-related disease [9–18]. Epidemiological studies estab-
lished an association between ibuprofen and reduced risk of
cataract [15]. In addition, ibuprofen protected diabetic rats
against cataractogenesis [13], and was shown to prevent
glycation [19] and carbamylation [20] of lens proteins in
vitro. Nevertheless, no appreciable interaction between
ibuprofen and lens proteins was found [21].
The mode of action of ibuprofen and the possible
involvement of its anti-inflammatory activity is, as yet,
unknown. However, it has to be emphasised that cataract
is a multifactorial disease and a delay in cataractogenesis
may be brought about in several ways, including the
protection of lens enzymes. Furthermore, ibuprofen metab-
olites are structural analogues of the parent drug and may
possess anti-cataract activity, contributing to the overall
anti-cataract property of ibuprofen (Fig. 1). We have exam-
ined these hypotheses and investigated the effects of ibu-
profen and its major metabolites on catalase and fumarase
during chemically induced inactivation.
The results from this work indicate that metabolites of
ibuprofen may play a role in its anti-cataract effect by
protecting lenticular enzymes. The results, in addition, show
that biotransformation of ibuprofen leads to products either
with superior protective action against enzyme inactivation,
or with reduced toxicity to enzymes, compared with the
parent drug. The penetration of ibuprofen metabolites into
lens was also explored.
2. Materials and methods
2.1. Chemicals
All the reagents were of analytical grade and pur-
chased from Aldrich Chemical Company (Gillingham, UK).
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Bovine liver catalase (EC 1.11.1.6) and porcine heart fumar-
ase (EC 4.2.1.2) were obtained from Sigma Company
(Gillingham, UK). Gibco BRL minimum essential medium
was used. The two metabolic products of ibuprofen and their
tritium-labelled counterparts were prepared by the methods
described previously [22]. Radioactivity measurement of the
solutions in Cocktail T (BDH) was carried out by liquid
scintillation counting. The buffer used throughout this work
was 50 mM sodium phosphate at pH 7.0. The incubation
mixtures were filtered through 0.2-Am polyethersulphone
syringe filters into heat-sterilised vials.
2.2. Preparation of [3H]-labelled ibuprofen
Ibuprofen (150 mg, 0.76 mmol) was dissolved in dry
tetrahydrofuran (5 ml), in a heat-dried vessel, protected
from moisture by sealing with a rubber septum. The
solution was maintained at 0 jC throughout the reaction.
Into this solution was injected, with stirring, lithium diiso-
propylamide (1.6 mmol) in cyclohexane (1.1 ml). The
mixture was stirred for 10 min, followed by addition of
tritium-enriched water (40 Al, 12 ACi) to neutralise the
ibuprofen anion. The mixture was stirred for 20 min, after
which time it was poured into water (40 ml) and acidified
with 10% aqueous hydrochloric acid. Ibuprofen was
extracted with ethyl acetate (3 20 ml). The combined
organic extracts were separated, washed with the aqueous
hydrochloric acid (3 5 ml) and water (10 ml), dried with
anhydrous magnesium sulfate and the solvent removed in
vacuo. To remove any remaining exchangeable tritium on
the carboxyl function, the residue was dissolved in absolute
ethanol and evaporated to dryness a few times until constant
specific radioactivity of the residue was obtained.
The crude ibuprofen was applied to a column (1.5 14
cm) packed with silica (63–200 Am, 60 A˚) which was then
eluted with 20% ethyl acetate in hexane. Fractions of 2-ml
volume each were collected and monitored by thin layer
chromatography (TLC) on silica gel in ethyl acetate/hexane
(3:5 v/v). The fractions containing ibuprofen were pooled
and evaporated to dryness. The resulting solid was crystal-
lised from petroleum ether (bp 60–80 jC), giving crystals
(70 mg) with mp (75–77 jC; literature [23], 75–77.5 jC),
TLC Rf (0.5) and
1H and 13C NMR spectra consistent with
authentic ibuprofen. The tritium-enriched ibuprofen had a
specific radioactivity of 0.9 mCi/mmol.
2.3. Incubation of catalase or fumarase with fructose,
cyanate or prednisolone in the presence of ibuprofen or one
of its major metabolites
Stock solutions of (A) 20 mM ibuprofen, hydroxy-
ibuprofen and carboxy-ibuprofen, and (B) 20 mM fructose,
20 mM potassium cyanate and 4 mM prednisolone 21-
hemisuccinate were prepared in the buffer. The pH of the A
solutions were adjusted back to 7.0 by addition of small
quantities of 20% aqueous sodium hydroxide.
Volumes of one of the A solutions (0.75 ml) and one of
the B solutions (0.75 ml) were mixed to give 10 mM
concentrations of ibuprofen or one of its metabolites, and
10 mM fructose or potassium cyanate, or 2 mM predni-
solone 21-hemisuccinate. Similarly, mixtures of each of the
A solutions (0.15 ml), the buffer (0.6 ml) and each of the
B solutions (0.75 ml) were prepared to give final concen-
trations of 2 mM ibuprofen or its metabolites, and 10 mM
fructose or potassium cyanate, or 2 mM prednisolone 21-
hemisuccinate. To each of the mixtures was added catalase
(5 units) or fumarase (5 units). The mixtures were incu-
bated at 37 jC with rocking. Simultaneously, two sets of
control experiments, containing catalase or fumarase but
no ibuprofen or its metabolites were set up, one with and
the other without fructose, cyanate or prednisolone. Ali-
quots (3 50 Al) were removed from the incubation
mixtures at intervals and their enzymatic activities were
determined as described below. The experiments were
repeated at least twice.
2.3.1. Catalase assay
The aliquots were assayed with 2.95 ml of 0.06%
hydrogen peroxide in the buffer. The decrease in absorb-
Fig. 1. Ibuprofen (I) and its major metabolites; the hydroxy-ibuprofen (II)
and carboxy-ibuprofen (III).
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ance at 240 nm, due to decomposition of hydrogen
peroxide, was measured over 2 min. The enzymatic ac-
tivity (expressed as change in absorbance per minute)
remaining after each time interval was expressed as
percentage of that at zero time for each incubation mix-
ture.
2.3.2. Fumarase assay
The aliquots were added to 2.95 ml of 20 mM malic acid
in the buffer. The increase in absorbance at 240 nm, due to
formation of fumaric acid, was monitored over 2 min.
Activity was expressed as for catalase.
2.4. Ibuprofen and hydroxy- and carboxy-ibuprofen binding
to catalase and fumarase
A solution of catalase (25 mg, 0.1 Amol) in the buffer
(1 ml) was placed in a dialysis sac, and dialysed against a
solution of the radiolabelled ibuprofen (2.06 mg, 10 Amol,
5.8 ACi), hydroxy-ibuprofen (2.22 mg, 10 Amol, 4.0 ACi)
or carboxy-ibuprofen (2.4 mg, 10 Amol, 9.0 ACi) in the
buffer (20 ml), giving a catalase/‘‘drug’’ molar ratio of
1:5. After overnight incubation at 4 jC, quadruplicate
aliquots (0.1 ml each) were removed from the inside
and outside of the dialysis sac and their radioactivity
was measured. Similarly, fumarase (4 mg, 0.02 Amol) in
the buffer (1 ml) was dialysed against radiolabelled
ibuprofen ( 0.49 mg, 2.4 Amol, 1.7 ACi), hydroxy-ibupro-
fen (0.53 mg, 2.4 Amol, 7.8 ACi) or carboxy-ibuprofen
(0.56 mg, 2.4 Amol, 2.1 ACi) in the buffer (20 ml), and
the radioactivity in the inside and outside of the sacs was
estimated.
2.5. Penetration of hydroxy- and carboxy-ibuprofen into
lens
Solutions of radiolabelled hydroxy-ibuprofen (13.5 mg,
60.1 Amol, 0.47 ACi) and carboxy-ibuprofen (18.0 mg,
70.3 Amol, 0.16 ACi) in minimum essential medium (15
ml) were separately prepared and their pH was adjusted
back to 7.0 by addition of small quantities of 20%
aqueous sodium hydroxide. The solutions were sterilised
by filtration through polyethersulphone syringe filters.
Lenses were immediately removed from fresh bovine eyes,
blotted with a filter paper and placed one in each of the
solutions, which were then incubated at room temperature
overnight. Duplicate incubations were simultaneously set
up.
Aliquots (4 0.1 ml) of each solution were removed and
their radioactivity was measured. The lenses were removed,
rinsed quickly with distilled water, blotted and homogenised
in 5 ml of the buffer. The volume of the lens was noted
by determining the increase in the volume of the homo-
genisation buffer. Radioactivity per milliliter of the lens
was estimated by liquid scintillation counting of aliquots
(4 0.1 ml) of the homogenate.
3. Results
3.1. Effect of ibuprofen and its metabolites on enzyme
inactivation by cyanate, fructose and prednisolone
Catalase and fumarase were individually incubated with
cyanate, fructose and prednisolone in the presence or
absence of ibuprofen or its major metabolic products.
Periodic measurement of enzymatic activity was made in
triplicate and mean values were taken. The catalase or
fumarase activities remaining at the end of incubations were
used for calculation (Tables 1 and 2). There was consistency
within repeats of each set when comparison was made with
controls.
We used concentrations of deleterious/protective reagents
higher than those encountered in vivo, in order to make
possible the study of biological processes, namely post-
translational modification and drug protection of proteins,
which take place over long periods of time in vivo. At the
reagent concentrations observed in vivo, very long incuba-
tion times would be needed to observe any protective or
deleterious effects in vitro, and bacterial decomposition
would occur.
3.1.1. Catalase
Incubation of catalase with 2 or 10 mM ibuprofen or its
metabolic products in the absence of the protein-modifying
agents appeared to have either a modestly beneficial effect
or no effect at all on catalase, that is 2 mM hydroxy-
ibuprofen and 10 mM ibuprofen significantly decreased the
activity loss at 37 jC by about 10%, whereas 2 and 10
mM carboxy-ibuprofen, 10 mM hydroxy-ibuprofen and 2
mM ibuprofen had no significant effect (Table 1). Fruc-
tose, prednisolone and cyanate inactivate catalase [24].
Both 2 and 10 mM concentrations of the drug and its
metabolites were used in protection against these noxious
compounds, and they were shown to offer varying degrees
of protection (Table 2). Both the 2 and 10 mM compounds
protected (6–21%) against carbamylation. 2 mM Ibupro-
Table 1
Effect of ibuprofen and its metabolites on catalase and fumarase at 37 jC
Catalasea Fumaraseb
No ibuprofen/metabolites 47.3F 2.9 50.6F 0.4
2 mM ibuprofen 48.1F 0.4 50.1F 0.3
2 mM hydroxy-ibuprofen 55.6F 1.8* 54.4F 0.2*
2 mM carboxy-ibuprofen 49.1F1.1 48.9F 0.7
10 mM ibuprofen 57.0F 1.3** 5.6 F 0.8
10 mM hydroxy-ibuprofen 45.3F 1.6 16.8F 1.7
10 mM carboxy-ibuprofen 46.2F 2.5 21.6F 1.0
Catalase or fumarase was incubated with ibuprofen, hydroxy-ibuprofen and
carboxy-ibuprofen for a7, b5 days. The enzyme activities as percentage at
zero time remaining after the incubation time, compared with the controls
(having no drug or metabolites) are shown (meansF S.D.).
* P< 0.05 (unpaired Student’s t-test, treatments vs. controls).
** P< 0.01 (unpaired Student’s t-test, treatments vs. controls).
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fen, hydroxy-ibuprofen and carboxy-ibuprofen, offered
about 6%, 9% and 21% protection, respectively, while at
10 mM concentrations, it was about 16%, 11% and 21%,
respectively. Fructose-induced loss of catalase activity was
decreased by 2 mM ibuprofen (13%), hydroxy-ibuprofen
(14%) and carboxy-ibuprofen (10%), while 10 mM con-
centrations provided 16%, 20% and 16% protection against
fructose-induced inactivation, respectively. Similarly, they
helped to retain (about 3–31%) catalase activity in the
presence of prednisolone; the 2 mM compounds decreased
inactivation by about 12% (ibuprofen), 3% (hydroxy-ibu-
profen) and 12% (carboxy-ibuprofen), and with the 10 mM
concentrations the protection obtained were 14%, 12% and
31%, respectively.
3.1.2. Fumarase
The 2 mM hydroxy-ibuprofen reduced inactivation of
fumarase at 37j slightly (about 4%), but significantly,
whereas 2 mM ibuprofen and carboxy-ibuprofen had no
significant effect (Table 1). Nonetheless, 10 mM ibuprofen,
hydroxy-ibuprofen and carboxy-ibuprofen inactivated fu-
marase by approximately 45%, 34% and 29%, respectively;
the metabolites being less detrimental than the parent
ibuprofen (Table 1). Therefore, we used only 2 mM con-
centrations of ibuprofen and its metabolic products in the
study involving fumarase (Table 2). The 2 mM ibuprofen,
hydroxy-ibuprofen and carboxy-ibuprofen protected fumar-
ase significantly against cyanate-induced inactivation by
about 18%, 9% and 8%, respectively. They offered nearly
26%, 18% and 17% protection against fructose-induced
inactivation. Prednisolone-induced inactivation of fumarase
was not affected significantly by 2 mM ibuprofen or its
metabolites.
3.2. Binding of ibuprofen and its metabolites to catalase and
fumarase
Possible binding of ibuprofen and its metabolites to
catalase and fumarase was examined by equilibrium dialysis
of a solution of catalase or fumarase against a solution of
each of ibuprofen and its metabolites, but there was no
difference between the inside and outside of the dialysis sac,
showing that catalase and fumarase do not bind ibuprofen or
its metabolic products (results not shown).
3.3. Penetration of ibuprofen metabolites into whole lenses
The pH of the incubation medium approximates the
physiological pH in lens. Minimum essential medium similar
to that in our experiments has been widely used for lens
incubations. Protein synthesis, amino acid uptake, transpar-
ency and ionic composition of the lens were maintained in
such a medium for periods exceeding or similar to those in
our work [25,26].
After overnight incubation of whole bovine lenses with
solutions of tritium-labelled hydroxy- and carboxy-ibupro-
fen in minimum essential medium, the lenses were homo-
genised. Radioactivity in the homogenates was estimated,
from which the quantities of the metabolites were calculated
(Table 3). The findings show that ibuprofen metabolites
penetrate into the lens and build up in it to concentrations
comparable with those of the surroundings.
4. Discussion
We examined our hypothesis that ibuprofen and/or its
major metabolites may offer protection against enzyme
inactivation, thus contributing to the anti-cataract property
associated with ibuprofen.
Table 3
Concentration of the metabolites in the lens and the medium
Medium Amol/mlF S.D. Lens Amol/mlF S.D.
Hydroxy-ibuprofen 4.3F 0.3 (4.2F 0.4) 2.2F 0.1 (2.3F 0.3)
Carboxy-ibuprofen 7.7F 0.4 (7.3F 0.4) 4.6F 0.25 (5.7F 0.4)
Lenses were incubated overnight in minimum essential medium containing
the radiolabelled metabolites. Radioactivity of the medium and the
homogenised lenses were used to calculate their concentrations. Values in
parentheses are from duplicate experiments.
Table 2
Protection of catalase and fumarase by ibuprofen and its metabolites against chemical inactivation
Catalase Fumarase
Cyanatea Fructosec Prednisoloned Cyanatec Fructosee Prednisolonef
No ibuprofen/metabolites 33.6F 2.6 20.0F 0.7 11.3F 1.1 12.6F 0.5 9.9F 1.0 31.7F 1.0
2 mM ibuprofen 39.9F 0.9* 33.0F 1.0** 23.1F 0.7** 30.4F 1.0** 35.9F 1.4** 31.9F 0.8
2 mM hydroxy-ibuprofen 43.1F 2.2** 34.2F 1.3** 14.7F 0.5** 21.7F 1.0** 27.8F 0.4** 29.7F 1.0
2 mM carboxy-ibuprofen 54.2F 1.6** 30.0F 0.7** 23.7F 0.9** 21.1F 0.7** 26.5F 2.1** 30.3F 0.8
10 mM ibuprofen 49.9F 0.8** 36.2F 0.5** 25.5F 0.8** – – –
10 mM hydroxy-ibuprofen 44.8F 0.9** 40.4F 0.9** 23.1F 0.8** – – –
10 mM carboxy-ibuprofen 54.9F 3.2** 36.6F 0.6** 42.2F 0.8** – – –
Catalase or fumarase was incubated with cyanate, fructose and prednisolone in the presence of ibuprofen or one of its metabolites for a 7,c 2,d3, e 5, f4 days. The
enzyme activities as percentage at zero time remaining after the incubation time, compared with the controls (having no drug or metabolites) are shown
(meansF S.D.).
* P < 0.05 (unpaired Student’s t-test, treatments vs controls).
* * P < 0.01 (unpaired Student’s t-test, treatments vs controls).
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We have found that catalase is protected by ibuprofen
and hydroxy- and carboxy-ibuprofen against fructose-,
cyanate- and prednisolone-induced inactivation, and the
carboxy-ibuprofen offers the highest protection when cyan-
ate or prednisolone is used to inactivate the enzyme.
Fumarase is also protected by these compounds against
fructose- and cyanate-inactivation, and ibuprofen is more
effective than its metabolites in protection against the
deleterious effects of cyanate and fructose. However, they
all appear to have negligible effect on prednisolone-induced
inactivation of the enzyme. An interesting observation in
this study is that ibuprofen and the metabolites at the lower
concentrations are protective, whereas the higher concen-
trations are harmful to fumarase, with the metabolites being
less damaging than ibuprofen.
The equilibrium dialysis experiments showed that ibu-
profen and its metabolites do not bind to catalase or
fumarase. Therefore, protection of the enzymes is brought
about by a mechanism(s) other than competition between
the drug/metabolites and protein-modifying agents for the
reaction sites on the enzymes.
The protection offered by the drug and its metabolites
may contribute to the reduced (ca. 50%) risk of cataract
development associated with ibuprofen [15].
Ibuprofen was shown to penetrate into the lens in vitro
[21], but we do not know how quickly it reaches the inside
of the lens in vivo, and how fast or whether at all it is
meta-bolised in the lens. Nevertheless, its metabolism else-
where in the body and/or in the lens produces metabolic
products which protect enzymes (catalase and fumarase),
and the pe-netration study demonstrated the ability of the
extra-lenticu-larly formed metabolites of ibuprofen to enter
the lens where they may contribute to the anti-cataract effect
of ibuprofen.
We obtained concentrations of metabolites in the lens
comparable to the medium. Therefore, the metabolites must
have penetrated well into the lens. Furthermore, most
metabolic activity in the lens is in the periphery, so it may
not be necessary for the drug to permeate right to the centre
to provide protection. Previously, we studied passive pene-
tration of ibuprofen into the lens [21], and found that
ibuprofen is distributed in lens cortex and nucleus (both
cortex and nucleus are therefore permeable to the drug).
The behaviour of the three compounds towards the
enzymes highlights possible diversity in the modes of action
of ibuprofen and its metabolites in bringing about anti-
cataract effects. Hence, in studying the function of ibupro-
fen, and perhaps other anti-cataract agents, in delaying
cataract development, we should not be searching for a
single mode of action; various protective mechanisms may
be expected for a multi-factorial disease, like cataract.
Acknowledgements
The authors are grateful to the Wellcome Trust for
financial support.
References
[1] J.J. Harding, Cataract: Biochemistry, Epidemiology and Pharmacol-
ogy, Chapman & Hall, London, 1991.
[2] K.C. Bhuyan, D.K. Bhuyan, S.M. Podos, Life Sci. 38 (1986) 1463–
1471.
[3] M.A. Smith, S. Taneda, P.L. Richey, S. Miyata, S.D. Yan, D. Stern,
L.M. Sayre, V.M. Monnier, G. Perry, Proc. Natl. Acad. Sci. U. S. A.
91 (1994) 5710–5714.
[4] L.K. Curtiss, J.L. Witztum, Diabetes 34 (1985) 452–461.
[5] J.H. Lee, D.H. Shin, A. Lupovitch, D.X. Shi, Biochem. Biophys. Res.
Commun. 123 (1984) 888–893.
[6] T. Miyata, C. van Ypersele de Strihou, K. Kurokawa, J.W. Baynes,
Kidney Int. 55 (1999) 389–399.
[7] R. Blakytny, J.J. Harding, Biochem. J. 288 (1992) 303–307.
[8] E. Ganea, J.J. Harding, Eur. J. Biochem. 231 (1995) 181–185.
[9] J.J. Harding, Drug Ther. 2 (1992) 287–300.
[10] N.C. Stratman, D.B. Carter, V.H. Sethy, Brain Res. Mol. Brain Res. 50
(1997) 107–112.
[11] M. Crompton, K.C. Rixon, J.J. Harding, Exp. Eye Res. 40 (1985)
279–311.
[12] M.S. Swamy, E.C. Abraham, Invest. Ophthalmol. Visual Sci. 30
(1989) 1120–1126.
[13] R. Blakytny, J.J. Harding, Exp. Eye Res. 54 (1992) 509–518.
[14] A. Hassan, J.B. Smith, W. Qin, D.L. Smith, Exp. Eye Res. 57 (1993)
29–35.
[15] J.J. Harding, M. Egerton, R.S. Harding, Acta Ophthalmol. 67 (1989)
518–524.
[16] G.P. Lim, F. Yang, T. Chu, P. Chen, W. Beech, B. Teter, T. Tran, O.
Ubeda, K.H. Ashe, S.A. Frautschy, G.M. Cole, J. Neurosci. 20 (2000)
5709–5714.
[17] J.A. Mitchell, T.D. Warner, Br. J. Pharmacol. 128 (1999) 1121–1132.
[18] N.S. Malik, K.M. Meek, Age Ageing 25 (1996) 279–284.
[19] R. Ajiboye, J.J. Harding, Exp. Eye Res. 49 (1989) 31–41.
[20] K.A. Roberts, J.J. Harding, Exp. Eye Res. 50 (1990) 157–164.
[21] A.Z. Shyadehi, J.J. Harding, Biochem. Pharmacol. 42 (1991) 2077–
2084.
[22] A.Z. Shyadehi, J.J. Harding, J. Labelled Compd. Radiopharm. 42
(1999) 207–213.
[23] J.S. Nicholson, S.S. Adams, Chem. Abstr. 61 (1964) 14591[Br pat
971700, 1964].
[24] D.W. Hook, J.J. Harding, Int. J. Biol. Macromol. 22 (1998) 295–306.
[25] J.M. Marcantonio, G. Duncan, Amino acid transport and crystallin
synthesis in the bovine lens, Exp. Eye Res. 36 (1983) 429–440.
[26] J. Marcantonio, G. Duncan, Amino acid transport and protein syn-
thesis in human normal and cataractous lenses, Curr. Eye Res. 6
(1987) 1299–1308.
A.Z. Shyadehi, J.J. Harding / Biochimica et Biophysica Acta 1587 (2002) 31–35 35
